CompletedPhase 2

Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy

Germany60 participantsStarted 2017-12-07

Plain-language summary

The purpose of the AveNEC trial is to investigate the clinical activity and safety of avelumab in patients with NEC G3 (WHO 2010), including "NET G3" who are progressive after first line chemotherapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection);
✕. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent;
✕. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)

What they're measuring

disease control rate (DCR) after 16 weeks of avelumab treatment

Timeframe: 16 weeks

Trial details

NCT IDNCT03352934

SponsorJohannes Gutenberg University Mainz

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-02-18

View on ClinicalTrials.gov More Cancer trials